Temat: "ErbB Receptors" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: FRET probe for detecting two mutations in one EGFR mRNA.
Autorzy:: Thu M; Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan. .
Yanai K; Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan. .
Shigeto H; Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 2217-14 Hayashi-cho, Takamatsu, Kagawa 761-0395, Japan.
Yamamura S; Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 2217-14 Hayashi-cho, Takamatsu, Kagawa 761-0395, Japan.
Watanabe K; Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan. .
Ohtsuki T; Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan. .; Pokaż więcej
Źródło:: The Analyst [Analyst] 2023 May 30; Vol. 148 (11), pp. 2626-2632. Date of Electronic Publication: 2023 May 30.
Typ publikacji:: Journal Article
MeSH Terms:: ErbB Receptors*/genetics
ErbB Receptors*/metabolism
Lung Neoplasms*/genetics
Humans ; Mutation ; RNA, Messenger/genetics ; Fluorescence Resonance Energy Transfer/methods ; Protein Kinase Inhibitors ; RNA

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 2.

Tytuł:: Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.
Autorzy:: Lu J; National-Local Joint Engineering Laboratory of Draggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Li J; National-Local Joint Engineering Laboratory of Draggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Lin Z; National-Local Joint Engineering Laboratory of Draggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Li H; National-Local Joint Engineering Laboratory of Draggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Lou L; National-Local Joint Engineering Laboratory of Draggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Ding W; National-Local Joint Engineering Laboratory of Draggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Ouyang S; National-Local Joint Engineering Laboratory of Draggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Wu Y; Department of Thoracic Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
Wen Y; Increasepharm (Hengqin) Innovative Medicine Institute Co. Ltd, Zhuhai, 519000, China.
Chen X; Increasepharm (Hengqin) Innovative Medicine Institute Co. Ltd, Zhuhai, 519000, China.
Yue P; Department of Medicine, Division of Hematology-Oncology, and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Wang Y; National-Local Joint Engineering Laboratory of Draggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Liu P; National-Local Joint Engineering Laboratory of Draggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Lu J; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, 519000, Macau. Electronic address: .
Zhang J; Department of Thoracic Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China. Electronic address: .
Feng W; Department of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, 52800, China. Electronic address: .
Zhang X; National-Local Joint Engineering Laboratory of Draggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China. Electronic address: .; Pokaż więcej
Źródło:: Cancer letters [Cancer Lett] 2023 Jun 28; Vol. 564, pp. 216205. Date of Electronic Publication: 2023 May 04.
Typ publikacji:: Journal Article
MeSH Terms:: ErbB Receptors*/metabolism
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; Gefitinib/pharmacology ; Gefitinib/therapeutic use ; Tumor-Associated Macrophages/metabolism ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Drug Resistance, Neoplasm ; Cell Line, Tumor ; Tumor Microenvironment ; STAT3 Transcription Factor/metabolism

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 3.

Tytuł:: Analysis of the in vitro function and internalization ability of a humanized EGFR antibody AE01 expressed by Chinese hamster ovary cells.
Autorzy:: Wu H; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
Ding X; School of Biotechnology, Jiangnan University, Wuxi, China.
Chen Y; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
Cai Y; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
Yang Z; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
Xu Q; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China.
Jin J; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China. Electronic address: .; Pokaż więcej
Źródło:: Protein expression and purification [Protein Expr Purif] 2023 Jun; Vol. 206, pp. 106243. Date of Electronic Publication: 2023 Feb 06.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: ErbB Receptors*
Antibodies*
Cricetinae ; Animals ; Mice ; Cricetulus ; CHO Cells ; Cell Line, Tumor

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 4.

Tytuł:: ERBB Receptors and Their Ligands in the Developing Mammary Glands of Different Species: Fifteen Characters in Search of an Author.
Autorzy:: Morato A; Department of Animal Science, University of California, Davis, One Shields Avenue, Davis, CA, 95616, USA. .
Accornero P; Department of Veterinary Science, University of Turin, Largo Paolo Braccini 2, Grugliasco, TO, 10095, Italy.
Hovey RC; Department of Animal Science, University of California, Davis, One Shields Avenue, Davis, CA, 95616, USA.; Pokaż więcej
Źródło:: Journal of mammary gland biology and neoplasia [J Mammary Gland Biol Neoplasia] 2023 May 23; Vol. 28 (1), pp. 10. Date of Electronic Publication: 2023 May 23.
Typ publikacji:: Journal Article; Review
MeSH Terms:: ErbB Receptors*
Mammary Glands, Human*/growth & development
Mammary Glands, Animal*/growth & development
Animals ; Female ; Humans ; Mice ; Disease Models, Animal ; Ligands

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 5.

Tytuł:: CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest.
Autorzy:: Cao W; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.; Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
Yao S; School of Medicine, Zhejiang University, Hangzhou 310058, China.
Li A; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.; Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
Chen H; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.; Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
Zhang E; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.; Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
Cao L; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.; Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
Zhang J; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.; Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
Hou Y; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.; Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
Dai Z; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.; Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
Chen J; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.; Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
Huang X; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.; Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
Yang L; Institute of Hematology, Zhejiang University, Hangzhou 310058, China. , .
Cai Z; Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China. .; Institute of Hematology, Zhejiang University, Hangzhou 310058, China. .; Pokaż więcej
Transliterated Title:: EGFR和HDAC双靶点抑制剂CUDC-101通过调控G2/M期阻滞增强硼替佐米抗骨髓瘤的作用.
Źródło:: Journal of Zhejiang University. Science. B [J Zhejiang Univ Sci B] 2023 May 15; Vol. 24 (5), pp. 442-454.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Bortezomib*/pharmacology
ErbB Receptors*/antagonists & inhibitors
Histone Deacetylase Inhibitors*/pharmacology
Multiple Myeloma*/drug therapy
Humans ; Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; G2 Phase Cell Cycle Checkpoints ; Histone Deacetylases/metabolism ; M Cells

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 6.

Tytuł:: Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling.
Autorzy:: Sugiyama MG; Department of Chemistry and Biology, Toronto Metropolitan University, Toronto, ON, Canada.
Brown AI; Department of Physics, Toronto Metropolitan University, Toronto, ON, Canada.
Vega-Lugo J; Department of Biophysics, UT Southwestern Medical Center, Dallas, TX, USA.
Borges JP; Program in Neuroscience and Mental Health, Hospital for Sick Children, Toronto, ON, Canada.
Scott AM; Olivia Newton-John Cancer Research Institute, La Trobe University, Melbourne, VIC, Australia.
Jaqaman K; Department of Biophysics, UT Southwestern Medical Center, Dallas, TX, USA.; Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, USA.
Fairn GD; Department of Pathology, Dalhousie University, Halifax, NS, Canada.
Antonescu CN; Department of Chemistry and Biology, Toronto Metropolitan University, Toronto, ON, Canada. .; Pokaż więcej
Źródło:: Nature communications [Nat Commun] 2023 May 09; Vol. 14 (1), pp. 2681. Date of Electronic Publication: 2023 May 09.
Typ publikacji:: Journal Article
MeSH Terms:: Signal Transduction*
ErbB Receptors*
Ligands ; Phosphorylation ; Tetraspanins

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 7.

Tytuł:: Gasdermin E regulates the stability and activation of EGFR in human non-small cell lung cancer cells.
Autorzy:: Xu L; Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Room N8-108, 72 Binhai Road, Qingdao, 266237, People's Republic of China.
Shi F; Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Room N8-108, 72 Binhai Road, Qingdao, 266237, People's Republic of China.
Wu Y; Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Room N8-108, 72 Binhai Road, Qingdao, 266237, People's Republic of China.
Yao S; Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Room N8-108, 72 Binhai Road, Qingdao, 266237, People's Republic of China.
Wang Y; Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Room N8-108, 72 Binhai Road, Qingdao, 266237, People's Republic of China.
Jiang X; National Glycoengineering Research Center, Shandong University, Qingdao, China.
Su L; Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Room N8-108, 72 Binhai Road, Qingdao, 266237, People's Republic of China. .
Liu X; Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Room N8-108, 72 Binhai Road, Qingdao, 266237, People's Republic of China. .; Pokaż więcej
Źródło:: Cell communication and signaling : CCS [Cell Commun Signal] 2023 Apr 21; Vol. 21 (1), pp. 83. Date of Electronic Publication: 2023 Apr 21.
Typ publikacji:: Video-Audio Media; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/metabolism
ErbB Receptors*/metabolism
Gasdermins*/metabolism
Lung Neoplasms*/pathology
Humans ; Cell Line, Tumor ; Cell Proliferation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities.
Autorzy:: Ho TLF; Disease Intervention Technology Lab (DITL), Institute of Molecular and Cell Biology, Agency for Science Technology and Research (A*STAR), Singapore, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Lee MY; Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Goh HC; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Ng GYN; Singapore Institute of Technology, Singapore, Singapore.
Lee JJH; Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Kannan S; Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Lim YT; Functional Proteomics Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; SingMass - National Mass Spectrometry Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Zhao T; Functional Proteomics Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; SingMass - National Mass Spectrometry Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Lim EKH; Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Phua CZJ; Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Lee YF; Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Lim RYX; Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Ng PJH; Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Yuan J; Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Chan DKH; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.; Division of Colorectal Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.
Lieske B; Division of Colorectal Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Chong CS; Division of Colorectal Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Lee KC; Division of Colorectal Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.
Lum J; Department of Pathology, National University Health System, Singapore, Singapore.
Cheong WK; Division of Colorectal Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.
Yeoh KG; University Surgical Cluster, National University Health System, Singapore, Singapore.
Tan KK; Division of Colorectal Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Sobota RM; Functional Proteomics Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; SingMass - National Mass Spectrometry Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Verma CS; Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; School of Biological Science, Nanyang Technological University, Singapore, Singapore.; Department of Biological Science, National University of Singapore, Singapore, Singapore.
Lane DP; Disease Intervention Technology Lab (DITL), Institute of Molecular and Cell Biology, Agency for Science Technology and Research (A*STAR), Singapore, Singapore.
Tam WL; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.; Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; School of Biological Science, Nanyang Technological University, Singapore, Singapore.; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; NUS Center for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Venkitaraman AR; Disease Intervention Technology Lab (DITL), Institute of Molecular and Cell Biology, Agency for Science Technology and Research (A*STAR), Singapore, Singapore. .; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. .; NUS Center for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. .; Pokaż więcej
Źródło:: Nature communications [Nat Commun] 2023 Mar 28; Vol. 14 (1), pp. 1726. Date of Electronic Publication: 2023 Mar 28.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Tumor Suppressor Protein p53*/metabolism
ErbB Receptors*/genetics
ErbB Receptors*/metabolism
Signal Transduction ; Transcriptional Activation ; Phosphorylation

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 9.

Tytuł:: Molecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino- and 6,6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model.
Autorzy:: Facchin C; Cancer Drug Research Laboratory, The Research Institute of the McGill University Health Center (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
Fraga-Timiraos AB; Cancer Drug Research Laboratory, The Research Institute of the McGill University Health Center (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
Schmitt J; Cancer Drug Research Laboratory, The Research Institute of the McGill University Health Center (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
Babaa N; Cancer Drug Research Laboratory, The Research Institute of the McGill University Health Center (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
Pannu N; Cancer Drug Research Laboratory, The Research Institute of the McGill University Health Center (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
Aliaga A; Cancer Drug Research Laboratory, The Research Institute of the McGill University Health Center (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
Larroque AL; Cancer Drug Research Laboratory, The Research Institute of the McGill University Health Center (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.
Jean-Claude BJ; Cancer Drug Research Laboratory, The Research Institute of the McGill University Health Center (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada.; Pokaż więcej
Źródło:: Cells [Cells] 2023 Mar 16; Vol. 12 (6). Date of Electronic Publication: 2023 Mar 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: ErbB Receptors*/drug effects
ErbB Receptors*/genetics
ErbB Receptors*/metabolism
Osteosarcoma*/drug therapy
Quinazolines*/pharmacology
Quinazolines*/therapeutic use
Animals ; Humans ; Mice ; DNA/chemistry ; Heterografts ; Prodrugs

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Autorzy:: Li MC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.; Biomedical Translation Research Center, Academia Sinica, Taipei City 115202, Taiwan, ROC.
Coumar MS; Department of Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet 605014, Pondicherry, India.
Lin SY; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Lin YS; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Huang GL; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Chen CH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Lien TW; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Wu YW; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei City 110301, Taiwan, ROC.
Chen YT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Chen CP; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Huang YC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Yeh KC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Yang CM; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Kalita B; Department of Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet 605014, Pondicherry, India.
Pan SL; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei City 110301, Taiwan, ROC.; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei City 110301, Taiwan, ROC.
Hsu TA; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Yeh TK; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Chen CT; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.
Hsieh HP; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan, ROC.; Biomedical Translation Research Center, Academia Sinica, Taipei City 115202, Taiwan, ROC.; Department of Chemistry, National Tsing Hua University, Hsinchu City 300044, Taiwan, ROC.; Pokaż więcej
Źródło:: Journal of medicinal chemistry [J Med Chem] 2023 Feb 23; Vol. 66 (4), pp. 2566-2588. Date of Electronic Publication: 2023 Feb 07.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents*/administration & dosage
Antineoplastic Agents*/pharmacology
Carcinoma, Non-Small-Cell Lung*/drug therapy
ErbB Receptors*/antagonists & inhibitors
ErbB Receptors*/genetics
Lung Neoplasms*/drug therapy
Protein Kinase Inhibitors*/administration & dosage
Protein Kinase Inhibitors*/pharmacology
Pyrimidines*/administration & dosage
Pyrimidines*/pharmacology
Animals ; Humans ; Mice ; Cell Line, Tumor ; Cell Proliferation ; Drug Resistance, Neoplasm ; Mutation ; Administration, Oral

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 11.

Tytuł:: Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer.
Autorzy:: Basse C; Institut du Thorax Curie Montsouris, 75005 Paris, France.; Paris Saclay Campus, Versailles Saint Quentin University, 78000 Versailles, France.
Trabelsi-Grati O; Genetics Department, Institut Curie, 75005 Paris, France.
Masliah J; Genetics Department, Institut Curie, 75005 Paris, France.
Callens C; Genetics Department, Institut Curie, 75005 Paris, France.
Kamal M; Department of Drug Development and Innovation, Institut Curie, 75005 Paris, France.
Freneaux P; Pathology Department, Institut Curie, 75005 Paris, France.
Klijanienko J; Pathology Department, Institut Curie, 75005 Paris, France.
Bieche I; Genetics Department, Institut Curie, 75005 Paris, France.; Genetics Department, University Paris Descartes, 75005 Paris, France.
Girard N; Institut du Thorax Curie Montsouris, 75005 Paris, France.; Paris Saclay Campus, Versailles Saint Quentin University, 78000 Versailles, France.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Feb 14; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 14.
Typ publikacji:: Case Reports
MeSH Terms:: Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Drug Resistance, Neoplasm*/genetics
ErbB Receptors*/antagonists & inhibitors
ErbB Receptors*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Disease Progression ; Ki-67 Antigen/genetics ; Mutation ; Protein Kinase Inhibitors/pharmacology

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth.
Autorzy:: Wisniewski DJ; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Liyasova MS; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Korrapati S; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Zhang X; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Ratnayake S; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, Maryland, USA.
Chen Q; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, Maryland, USA.
Gilbert SF; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Catalano A; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Voeller D; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Meerzaman D; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, Maryland, USA.
Guha U; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Porat-Shliom N; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Annunziata CM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Lipkowitz S; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. Electronic address: .; Pokaż więcej
Źródło:: The Journal of biological chemistry [J Biol Chem] 2023 Jan; Vol. 299 (1), pp. 102766. Date of Electronic Publication: 2022 Dec 05.
Typ publikacji:: Journal Article; Research Support, N.I.H., Intramural
MeSH Terms:: ErbB Receptors*/genetics
ErbB Receptors*/metabolism
Neoplasms*/genetics
Neoplasms*/physiopathology
Proto-Oncogene Proteins c-cbl*/genetics
Proto-Oncogene Proteins c-cbl*/metabolism
Animals ; Humans ; Mice ; Epidermal Growth Factor/metabolism ; HEK293 Cells ; HeLa Cells ; Mice, Nude ; Phosphorylation ; Ubiquitination ; Membrane Proteins/metabolism ; Proteolysis ; Gene Expression Regulation, Neoplastic

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 13.

Tytuł:: Generation of an anti-idiotypic affibody-based masking domain for conditional activation of EGFR-targeting.
Autorzy:: Mestre Borras A; Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.
Dahlsson Leitao C; Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.
Ståhl S; Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.
Löfblom J; Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden. Electronic address: .; Pokaż więcej
Źródło:: New biotechnology [N Biotechnol] 2023 Mar 25; Vol. 73, pp. 9-18. Date of Electronic Publication: 2022 Dec 14.
Typ publikacji:: Journal Article
MeSH Terms:: ErbB Receptors*/metabolism
Peptide Hydrolases*

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 14.

Tytuł:: Domain Architecture of the Nonreceptor Tyrosine Kinase Ack1.
Autorzy:: Kan Y; Department of Physiology and Biophysics, School of Medicine, Stony Brook University, Stony Brook, NY 11794-8661, USA.
Paung Y; Department of Pharmacology, School of Medicine, Stony Brook University, Stony Brook, NY 11794-8661, USA.
Seeliger MA; Department of Pharmacology, School of Medicine, Stony Brook University, Stony Brook, NY 11794-8661, USA.
Miller WT; Department of Physiology and Biophysics, School of Medicine, Stony Brook University, Stony Brook, NY 11794-8661, USA.; Department of Veterans Affairs Medical Center, Northport, NY 11768-2200, USA.; Pokaż więcej
Źródło:: Cells [Cells] 2023 Mar 15; Vol. 12 (6). Date of Electronic Publication: 2023 Mar 15.
Typ publikacji:: Journal Article; Review; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
MeSH Terms:: ErbB Receptors*/metabolism
Protein-Tyrosine Kinases*/chemistry
Protein-Tyrosine Kinases*/metabolism
Protein-Tyrosine Kinases*/physiology
Protein Domains ; Receptor Protein-Tyrosine Kinases/metabolism ; src Homology Domains

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: EGFR-targeted hybrid lipid nanoparticles for chemo-photothermal therapy against colorectal cancer cells.
Autorzy:: Fang F; School of Pharmacy, Wannan Medical College, Wuhu 241002, China.
Zhang X; School of Chemistry and Materials Science, Anhui Normal University, Wuhu 241002, China.
Tang J; School of Pharmacy, Wannan Medical College, Wuhu 241002, China.
Wang Y; School of Pharmacy, Wannan Medical College, Wuhu 241002, China; Department of pharmacy, Chaohu Hospital of Anhui Medical University, Hefei 238000, China.
Xu J; School of Pharmacy, Wannan Medical College, Wuhu 241002, China.
Sun Y; School of Pharmacy, Wannan Medical College, Wuhu 241002, China; Institute of Synthesis and Application of Medical Materials, Wannan Medical College, Wuhu 241002, China. Electronic address: .; Pokaż więcej
Źródło:: Chemistry and physics of lipids [Chem Phys Lipids] 2023 Mar; Vol. 251, pp. 105280. Date of Electronic Publication: 2023 Jan 10.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Colorectal Neoplasms*/drug therapy
ErbB Receptors*/metabolism
Nanoparticles*
Photothermal Therapy*
Molecular Targeted Therapy*
Humans ; Cell Line, Tumor ; Cetuximab/administration & dosage ; Cetuximab/pharmacology ; Drug Delivery Systems ; Lipids ; Polymers

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 16.

Tytuł:: Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents.
Autorzy:: Arafet K; Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parco Area delle Scienze 27/A, I- 43124 Parma, Italy.; BioComp Group, Institute of Advanced Materials (INAM), Universitat Jaume I, 12071 Castelló, Spain.
Scalvini L; Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parco Area delle Scienze 27/A, I- 43124 Parma, Italy.
Galvani F; Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parco Area delle Scienze 27/A, I- 43124 Parma, Italy.
Martí S; BioComp Group, Institute of Advanced Materials (INAM), Universitat Jaume I, 12071 Castelló, Spain.
Moliner V; BioComp Group, Institute of Advanced Materials (INAM), Universitat Jaume I, 12071 Castelló, Spain.
Mor M; Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parco Area delle Scienze 27/A, I- 43124 Parma, Italy.; Microbiome Research Hub, University of Parma, Parco Area delle Scienze 11/A, I-43124 Parma, Italy.
Lodola A; Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parco Area delle Scienze 27/A, I- 43124 Parma, Italy.; Pokaż więcej
Źródło:: Journal of chemical information and modeling [J Chem Inf Model] 2023 Feb 27; Vol. 63 (4), pp. 1301-1312. Date of Electronic Publication: 2023 Feb 10.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: ErbB Receptors*/metabolism
Lung Neoplasms*/genetics
Humans ; Mutation ; Lysine ; Protein Kinase Inhibitors/pharmacology ; Drug Resistance, Neoplasm/genetics

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 17.

Tytuł:: Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
Autorzy:: Zhao N; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
Wu ZP; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
Yang J; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
Feng WN; Department of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, China.
Yang SL; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
Luo Y; Department of Traditional Chinese Medicine, The First People's Hospital of Foshan, Foshan, China.
Ye J; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
Wang F; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
Zhang XW; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
Xiao Y; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
Wu LL; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China.
Gu WQ; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China. .; Pokaż więcej
Źródło:: World journal of surgical oncology [World J Surg Oncol] 2023 Feb 13; Vol. 21 (1), pp. 45. Date of Electronic Publication: 2023 Feb 13.
Typ publikacji:: Meta-Analysis; Journal Article; Review
MeSH Terms:: Antineoplastic Agents*/therapeutic use
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/surgery
ErbB Receptors*/antagonists & inhibitors
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/surgery
Humans ; Mutation ; Randomized Controlled Trials as Topic ; Tyrosine Protein Kinase Inhibitors/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Case report: identification of EGFR R776H and FANCE R381H germline mutations in a patient with multiple pulmonary nodules.
Autorzy:: Wu Z; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Wang Y; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jin L; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Wei J; Department of Respiratory Medicine, Jiangsu Suining People's Hospital, Xuzhou, China.
Han L; ChosenMed Technology (Beijing) Co., Ltd., Beijing, China.
Su J; ChosenMed Technology (Beijing) Co., Ltd., Beijing, China.
Cao S; ChosenMed Technology (Beijing) Co., Ltd., Beijing, China.
Liu S; ChosenMed Technology (Beijing) Co., Ltd., Beijing, China.
Duan X; ChosenMed Technology (Beijing) Co., Ltd., Beijing, China. .
Zhao X; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. .; Pokaż więcej
Źródło:: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Feb; Vol. 149 (2), pp. 921-927. Date of Electronic Publication: 2022 Sep 26.
Typ publikacji:: Case Reports; Journal Article; Letter
MeSH Terms:: ErbB Receptors*/genetics
Lung Neoplasms*/diagnostic imaging
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Multiple Pulmonary Nodules*/genetics
Fanconi Anemia Complementation Group E Protein*/genetics
Aged ; Child ; Female ; Humans ; Germ-Line Mutation ; Lung/pathology

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 19.

Tytuł:: Identification of a Suitable Untargeted Agent for the Clinical Translation of ABY-029 Paired-Agent Imaging in Fluorescence-Guided Surgery.
Autorzy:: Wang C; Thayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Xu X; Thayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Hodge S; Thayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Chen EY; Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Hoopes PJ; Thayer School of Engineering, Dartmouth College, Hanover, NH, USA.; Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Tichauer KM; Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA.
Samkoe KS; Thayer School of Engineering, Dartmouth College, Hanover, NH, USA. .; Geisel School of Medicine, Dartmouth College, Hanover, NH, USA. .; Pokaż więcej
Źródło:: Molecular imaging and biology [Mol Imaging Biol] 2023 Feb; Vol. 25 (1), pp. 97-109. Date of Electronic Publication: 2021 Oct 12.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: ErbB Receptors*/metabolism
Neoplasms*
Humans ; Fluorescence ; Methylene Blue

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 20.

Tytuł:: Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.
Autorzy:: Ishikawa E; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan.
Yokoyama Y; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan. .; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, 105-8512, Tokyo, Japan. .
Chishima H; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, 105-8512, Tokyo, Japan.
Kasai H; Laboratory of Pharmacometrics and Systems Pharmacology, Keio Frontier Research and Education Collaboration Square (K-FRECS) at Tonomachi, Keio University, Kawasaki, Kanagawa, Japan.
Kuniyoshi O; Department of Pharmacy, Ageo Central General Hospital, Ageo, Japan.
Kimura M; Department of Pharmacy, Keio University Hospital, Tokyo, Japan.
Hakamata J; Department of Pharmacy, Keio University Hospital, Tokyo, Japan.
Nakada H; Department of Pharmacy, Keio University Hospital, Tokyo, Japan.
Suehiro N; Department of Pharmacy, Keio University Hospital, Tokyo, Japan.
Nakaya N; Department of Oncology, Ageo Central General Hospital, Ageo, Japan.
Nakajima H; Department of Oncology, Ageo Central General Hospital, Ageo, Japan.
Ikemura S; Department of Respiratory Medicine, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Kawada I; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.; Health Center, Keio University, Yokohama, Japan.
Yasuda H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Terai H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.; Keio Cancer Center, School of Medicine, Keio University School of Medicine, Tokyo, Japan.
Jibiki A; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, 105-8512, Tokyo, Japan.
Kawazoe H; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan.; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, 105-8512, Tokyo, Japan.
Soejima K; Department of Respiratory Medicine, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Muramatsu H; Department of Pharmacy, Keio University Hospital, Tokyo, Japan.
Suzuki S; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan.; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, 105-8512, Tokyo, Japan.
Nakamura T; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan.; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, 105-8512, Tokyo, Japan.; Pokaż więcej
Źródło:: Investigational new drugs [Invest New Drugs] 2023 Feb; Vol. 41 (1), pp. 122-133. Date of Electronic Publication: 2023 Jan 13.
Typ publikacji:: Observational Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
ErbB Receptors*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
ATP Binding Cassette Transporter, Subfamily B, Member 2*/genetics
ATP Binding Cassette Transporter, Subfamily B*/genetics
Humans ; Aniline Compounds/adverse effects ; Aniline Compounds/pharmacokinetics ; East Asian People ; Mutation ; Pharmacogenetics ; Prospective Studies ; Protein Kinase Inhibitors/pharmacokinetics

Czasopismo naukowe

na półce

Szczegóły

Informacja

Wyszukujesz frazę ""ErbB Receptors"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język